Vitamin D is a secosteroid hormone regulating calcium and phosphate metabolism, immune response and brain development. Low blood 25(OH)D levels have been reported in patients affected by infectious diseases caused by parasites, including malaria. Despite the high effectiveness of antimalarials, malaria is burdened with high morbidity and mortality, and the search for additional therapies is rapidly growing. Furthermore, available preventive measures have proved to be barely effective so far.
Vitamin D in malaria: more hypotheses than clues Giulia 
Introduction
Vitamin D is a secosteroid hormone regulating the expression of almost 900 genes [1] and it is involved in the regulation of calcium and phosphate metabolism, immune response and brain development [2, 3] . Low blood Vitamin D levels have been reported in patients affected by infectious diseases, including those caused by parasites [4] . Among these, the pathogen causing malaria in humans, Plasmodium falciparum, was responsible for the death of almost 365.000 African children under the age of five in 2016 [5, 6] . Even though existing antimalarials are highlyeffective, malaria is burdened with high morbidity and mortality [7] , which means that the search for additional therapies to administer along with antimalarial treatments is rapidly growing. Furthermore, available preventive measures, including vector control programs, chemoprevention and vaccinations, have proved to be barely effective so far, mainly due to insecticides and drugs resistance in vectors and plasmodium [8] . Finding new prevention and therapy tools is a matter of urgency. Studies on animal models and humans have hypothesised some mechanisms by which the hormone can influence malaria pathogenesis, and the role of Vitamin D analogues supplementation in preventing and treating this disease has been suggested [9] .
The purpose of this paper is to highlight the mechanisms by which Vitamin D can influence the pathogenesis of malaria and provide a critical review of the studies evaluating the association of Vitamin D and malaria, in order to determine whether and how supplementation can be useful in preventing and treating patients affected by this disease.
rapid response steroid binding-MARRS or ERp57) pathway [12] . Both nuclear and surface receptors signalling carry out genomic and non-genomic actions ( Fig. 1) [13]. While VDR-mediated activities seem to be involved in modulation of the immune response [14] , the PDIA3 signalling pathway is deemed to be implicated in the regulation of brain development and function [15] .
Low 25(OH)D circulating levels, as well as genetic variants of VDR, have been reported in patients affected by infectious, autoimmune and neurological diseases [16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26] . Notably, multiple lines of evidence show that Vitamin D may play a role in the pathogenesis of infectious diseases [27, 28] . In autoimmune diseases, a growing body of data documented a role for Vitamin D either as a pathogenic factor or a serum biomarker [24] . Also, Vitamin D has been proposed as a serum biomarker in neurodegenerative disorders, along with inflammatory and cardiovascular markers [29, 30, 31, 32, 33, 34] . 
Immunomodulation by vitamin D
The immune system is designed to protect the body against pathogens and cell damage acting in conjunction with the Central Nervous System (CNS) [39] . has also been suggested [51] . Finally, the hormone determines the expression of cathelicidin and defensins, antimicrobial peptides involved in the defence against pathogens [52, 53] . Vitamin D comprehensive action results in the increase of antimicrobial activity of the innate response and the decreasing of the adaptive response proinflammatory effects. It is also known that 1,25(OH)2D acts on the endothelium, e.g. increasing the expression of vascular cell adhesion molecule 1 (VCAM-1) [54] .
The role of vitamin D in protection against pathogens
Active Vitamin D exerts an antibacterial and antiviral action mediated by defensins and cathelicidin. An antiparasitic action through the production of lactoferrin, cathelicidin-related antimicrobial peptide, reactive oxygen species and the phospholipids biosynthesis inhibition has been documented in Plasmodium falciparum and Plasmodium yoelii [55, 56, 57, 58] . Besides, 1,25(OH)2D influences the defence against pathogens by modulating T-helper lymphocytes subsets balance. When considering the role of the active hormone in T cells differentiation, it has to be borne in mind that both Th balance and Treg function have an impact on immune response efficacy and safety against pathogens. Indeed, Th1 cells provide an effective defence against pathogens, but, on the other hand, a Th1 uncontrolled response can result in self-reactive and pathological phenomena. Th2 cells exert an anti-inflammatory action along with the defence against helminth, but, on the other hand, a Th2 excessive response can undermine pathogens clearance and infections containment. Finally, Treg cells play a role in regulating/suppressing effector T cells and they also suppress pro-inflammatory cytokines action [59] . Active Vitamin D can exert a protective role against pathogens by modulating Th cells balance and enhancing the development of Treg.
1,25(OH)2D immunomodulatory activity has been associated with some parasitic infections, such as malaria (Fig. 2) . Th1 excessive response, Th2 response mitigation and Treg cells dysfunction represent mechanisms involved in the onset and development of malaria [8, 9] , and these effects can be limited by the action of 1,25(OH)2D
on the immune response. Further, the hormone inhibits the synthesis of some proinflammatory cytokines such as IFN-g and TNF-a, which are involved in the development of cerebral malaria (CM), an often fatal multifactoral pathogenesis syndrome [60] . [61, 62, 63, 64, 65] . Vitamin D in such diseases has been studied i) in relation to pathogenesis; ii) as a risk factor for the onset of the infection and for the development of sepsis (when <30 ng/ml); iii) as a biomarker of disease severity, along with well-established biomarkers [55, 65, 66, 67] .
Many studies carried out on large samples have shown an association between 25(OH)D circulating levels and RTI onset, both in children and adults, but, a more recent small sample size study has shown opposite results [68, 69, 70] . Some of the randomized controlled trials (RCTs) evaluating Vitamin D analogues supplementation effects in patients affected by RTI supposedly show encouraging results, also in terms of safety (no adverse reactions reported in most RCTs) [70] . However, other RTCs contradicted these results [71, 72] . It should be noted that Vitamin D trials generally enrol subjects who are not 25(OH)D deficient, thus, failure in finding a beneficial effect of supplementation could depend on this issue [73] . The association between Vitamin D deficiency and tuberculosis has been widely documented. Vitamin D deficiency has been considered as an independent risk factor for tuberculosis onset [74, 75, 76, 77, 78] . However, it has to be noted that RCTs on Vitamin D analogues supplementation in patients affected by tuberculosis present some limitations, e.g. large discrepancies as far as doses and primary outcomes are concerned [79, 80, 81, 82] .
Vitamin D has been widely studied in HIV and Epstein Barr virus infections. As regards patients with HIV infection or affected by acquired immunodeficiency syndrome (AIDS), an association between 25(OH)D blood levels and CD4þ lymphocytes count, all-cause mortality and bone fractures risk has been reported [83, 84, 85] . However, interventional studies in this setting are not available.
The relationship between Vitamin D and Epstein Barr Virus infection has been mainly evaluated in patients affected by multiple sclerosis (MS), suggesting the role of Vitamin D as an environmental factor involved in the pathogenesis of the disease [86] .
Few studies on animal models have shown that low dose supplementation of Vitamin D analogues in Candida-infected mice can reduce fungal burden and improve their survival when compared with Vitamin D-untreated mice [62] . Furthermore, some in vitro studies have shown that Vitamin D deficiency represents a risk factor for the nephrotoxicity induced by Amphotericin B, an antifungal agent used to treat systemic mycoses [87] .
Finally, few studies have investigated the role of Vitamin D in sepsis and, although two systematic reviews have shown an association between sepsis risk and mortality in these patients, results should be taken with a grain of salt, because most of the studies included were retrospective and because Vitamin D deficiency and insufficiency definition differed considerably according to the studies [64] . Few RCTs have been carried out on septic patients, reporting disheartening results [88] . However, a recent review suggested that high-dose Vitamin D analogues supplementation could be beneficial in intensive care units patients (ICU) [89] . Further, the Authors suggested that ICU patients might display Vitamin D deficiency due to many reasons, including hepatic and kidney dysfunction.
The role of vitamin D in malaria
The study on the role of Vitamin D in malaria is rooted in the past. At the end of the '50s, and then in the '80s, some studies have shown apparently promising results suggesting an antiplasmodial activity of active Vitamin D [90, 91, 92] . On the heels of a sort of enthusiasm, many researchers have deepened this topic to the present day. The scientific rationale supporting these studies seemed to be reasonable and intriguing: indeed, it is known that, when parasitic diseases occur, the modulation 
Studies on animal models
A study aiming to evaluate melanin protective effect on malaria infection by Weisberg [95] shows that Vitamin D does not affect the survival of Plasmodium berghei against ECM, it would be necessary to recognise that all the mice died after three weeks, regardless of the treatment with Vitamin D. Maybe it would be more appropriate to discuss about lengthening of the survival rather than a protection. The same team carried out another experiment this year, orally administering Vitamin D before infecting C57BL/6 mice with PbA (50 mg/Kg/day before infection for five consecutive days) to evaluate beneficial effects of Vitamin D pretreatment on CM progression [9] . Achieving a similar result (treated mice survived from 4 to 9 days more than untreated mice), the Authors present it as a protection by Vitamin D against CM, but it should not be overlooked that, regardless of the Vitamin D pretreatment, all the mice developed CM symptoms within 5 days from the infection and then died. It is also worth mentioning the experiment conducted by Yamamoto [5] : he tested the efficacy of Vitamin D and 22-oxacalcitriol (22-OCT); the latter was used because it causes less hypercalcaemia and weight loss than Vitamin D. Using VDR-knockout mice, the Authors suggested that both Vitamin D and 22-OCT perform their alleged antiplasmodial action through direct and indirect mechanisms, both VDRindependent and VDR-mediated. However, the Authors suggested that further studies are needed to explain the physiological mechanisms underlying this antiplasmodial activity. Moreover, the Authors infected BALB/c mice and B6 mice with a PcAS subspecies that is lethal in the first rodent type and that leads to partial mortality in the second type. Administering Vitamin D and 22-OCT, they obtain opposite effects on the two types of animals: 50% of BALB/c mice died before the control, because of their high susceptibility to Vitamin D toxic effects, while 100% of treated-B6 mice survived. It would be interesting to investigate the reasons why Vitamin D and 22-OCT exerted marked toxicity in a case and a beneficial effect on the other.
Dwivedi [7] has recently tested the efficacy against CM of combined treatment arteether-group (25 mg/kg À1 a/b arteether on day 6 followed by 12.5 mg/ kg À1 arteether on day 7 and 8 via intramuscular injection along with 50 mg/ kg À1 for 3 days via intramuscular injection) a significant survival rate compared to the other groups was observed. It should be noted that an additional a/b arteether high dose-group (50 mg/kg À1 a/b arteether on day 6 followed by 25 mg/kg À1 arteether on day 7 and 8 via intramuscular injection) survived more than Vitamin Dþa/b arteether-group (77% vs 73% respectively). Moreover, the evaluation of blood-brain barrier integrity, affected by injection of Evan Blue and calculating its concentration in brain parenchyma, showed that there were no differences between a/b arteether-treated group and Vitamin Dþa/b arteether-treated one.
Studies on humans
There are few studies on humans, and they could be challenging to interpret, because they have often been carried out on small samples and, in any case, they have produced mixed results [63, 96] (Table 1) . Sudfeld made considerable efforts to study the association between Vitamin D circulating levels and the onset of malaria in children and adults, testing large patient cohorts [4] . In 2013, the Authors studied 1105 adults affected by HIV from Tanzania and measured Vitamin D in order to understand if an association between the hormone and the occurrence of some infectious diseases, including malaria, exists [97] . People receiving the diagnosis at baseline and within the first month after the baseline visit were excluded from the study, in order to minimise reverse causation risk. Furthermore, he analysed 25(OH)D levels continuously, to get around the issue of consensus lacking on ideal hormone levels.
52% of patients showed 25(OH)D < 30 ng/ml levels and there were 356 incident malaria cases during a median follow-up of 20.6 months. No association between Vitamin D status and malaria incidence has been found using univariate and multivariate analyses.
In 2015, the same Authors reported surprising results when they investigated the association between 25(OH)D levels and mortality in 1200 HIV-infected and noninfected children [98] . Indeed, they indicated an association between higher 25(OH)D (>30 ng/ml) levels and malaria diagnosis in HIV-infected children (Incident Rate Ratio-IRR: 1.71; 95%: 1.15, 2.54; p < 0,01 and IRR:1.37; CI: 1.09 1.73; p < 0,01). The clinical diagnosis was made according to WHO's Integrated Management of Childhood Illness guidelines [99] during a 24 months follow-up, and, in some cases, was confirmed by parasitemia in a Giemsa-stained blood smear. In order to provide a mechanistic explanation of the result, the Authors suggested that the Th2 excessive response promoted by Vitamin D could play a role in reducing plasmodium clearance. However, they pointed out that the observational nature of the study leaves room for unmeasured and residual confounders that might have influenced the association between malaria and Vitamin D. For instance, children more exposed to sunlight, who synthesise more Vitamin D, are also more exposed to SMA vs 20 controls). 95% of children with severe malaria presented plasma 25(OH)D < 30 ng/ml and logistic regression analysis showed that the odds having severe malaria decreased by 9% for each ng/ml of Vitamin D (OR: 0.9; CI 95% 0.84.
1.0). However, interpreting Cusik results, it should be taken into account that he tested a small sample and that 80% of controls presented Vitamin D insufficiency.
It is well known that dark-skinned populations are more exposed to lower 25(OH) D levels, because of some factors including low-Vitamin D diet [96, 101] . More recently, Toko et al. have assessed the association between plasma 25(OH)D concentrations and pregnancy outcomes in 63 women from western Kenya [63] . 39% of women included in this study presented malaria infection and the binomial regression analysis showed that no association between malaria infection and Vitamin D status.
Studies have shown that malaria is more often diagnosed in the rainy season, also because rainfalls and floods can contribute to developing an ecosystem that favours mosquito breeding [102] . Since Vitamin D concentration in this season is lower, supplementation might help to reduce the risk of malaria. Further, supplementing in the rainy season would not increase the risk of some bacterial infections which have been positively correlated with Vitamin D and UVB [103] .
VDR up-regulation has been related to the intestinal damage occurring during Plasmodium chabaudi infection, suggesting that it could depend on VDR-mediated NFkB activation [104] . Finally, a very recent study has assayed 109 patients affected by malaria for VDR single nucleotide polymorphism (SNP rs 731236), finding no association between SNP rs 731236 and both infection susceptibility and disease severity [105] .
Conclusions
There are few studies on the association between Vitamin D and malaria producing disagreeing results. Although the pathogenic mechanisms by which immunomodulation by Vitamin D can influence the onset and progression of malaria have been suggested, it can not be stated that low 25(OH)D circulating levels contribute to the pathogenesis of the disease. Generally speaking, there is not clear evidence on the preventive and/or therapeutic efficacy of Vitamin D against malaria. RCTs are needed in order to understand whether Vitamin D administration might play a role in preventing or in treating malaria.
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